Latest Financial Results
FY 2022
Fiscal Year Ended Dec 31, 2022
Sign up for Email Alerts
Sign up todayStock Information
Syros Pharmaceuticals, Inc.
Symbol
Nasdaq: SYRSPrice
Change
Volume
52 week Low/High
Day Low/High
Company Overview
Syros is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is focused on advancing a late-stage clinical pipeline, including tamibarotene, an oral selective RARĪ± agonist in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression, and SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia. Syros is seeking partnerships for SY-5609, a highly selective and potent CDK7 inhibitor in clinical development for the treatment of select solid tumors, and multiple preclinical programs in oncology and monogenic diseases.
Latest Presentation
IR Contact Information
Investor Relations
Syros Pharmaceuticals
Karen Hunady
Director of Corporate Communications & Investor Relations
khunady@syros.com
Stern Investor Relations, Inc.
Hannah Deresiewicz
hannahd@sternir.com
Transfer Agent
Computershare Trust Company, N.A.